The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Abstract
Selective delivery of therapeutic molecules to primary and metastatic tumors is optimal for effective cancer therapy. A liposomal nanodelivery complex (scL) for systemic, tumor-targeting delivery of anticancer therapeutics has been developed. scL employs an anti-transferrin receptor (TfR), scFv as the targeting molecule. Loss of p53 suppressor function, through mutations or inactivation of the p53 pathway, is present in most human cancers. Rather than being transiently permissive for tumor initiation, persistence of p53 dysfunction is a continuing requirement for maintaining tumor growth. Herein, we report results of a first-in-man Phase I clinical trial of restoration of the normal human tumor suppressor gene p53 using the scL nanocomplex (SGT-53). Minimal side effects were observed in this trial in patients with advanced solid tumors. Furthermore, the majority of patients demonstrated stable disease. One patient with adenoid cystic carcinoma had his status changed from unresectable to resectable after one treatment cycle. More significantly, we observed an accumulation of the transgene in metastatic tumors, but not in normal skin tissue, in a dose-related manner. These results show not only that systemically delivered SGT-53 is well tolerated and exhibits anticancer activity, but also supply evidence of targeted tumor delivery of SGT-53 to metastatic lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGT-53, a nanoparticle that has WT TP53 cDNA packed in a plasmid, was shown to inhibit tumor growth, increase the induction of apoptosis, and significantly improve median survival in patients treated in combination with temozolomide.405”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [405]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
Research works printed but not linked: 42
- Lane, 1995, On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage, Philos Trans R Soc Lond, B, Biol Sci, 347, 83, 10.1098/rstb.1995.0013 · DOI
- Levine, 1991, The p53 tumour suppressor gene, Nature, 351, 453, 10.1038/351453a0 · DOI · Paper page
- Hollstein, 1994, Database of p53 gene somatic mutations in human tumors and cell lines, Nucleic Acids Res, 22, 3551
- Gudkov, 2003, The role of p53 in determining sensitivity to radiotherapy, Nat Rev Cancer, 3, 117, 10.1038/nrc992 · DOI · Paper page
- Isobe, 1994, Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection, Jpn J Cancer Res, 85, 1240, 10.1111/j.1349-7006.1994.tb02936.x · DOI
- Iwaya, 1991, Nuclear p53 immunoreaction associated with poor prognosis of breast cancer, Jpn J Cancer Res, 82, 835, 10.1111/j.1349-7006.1991.tb02710.x · DOI · Paper page
- Quinlan, 1992, Accumulation of p53 protein correlates with a poor prognosis in human lung cancer, Cancer Res, 52, 4828
- Thorlacius, 1993, Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor, Cancer Res, 53, 1637
- Thor, 1992, Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers, J Natl Cancer Inst, 84, 845, 10.1093/jnci/84.11.845 · DOI · Paper page
- Allred, 1993, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer, J Natl Cancer Inst, 85, 200, 10.1093/jnci/85.3.200 · DOI · Paper page
- Hamada, 1996, The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers, J Cancer Res Clin Oncol, 122, 360, 10.1007/BF01220804 · DOI
- Xu, 1999, Systemic p53 gene therapy in combination with radiation results in human tumor regression, Tumor Targeting, 4, 92
- Cicalese, 2009, The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells, Cell, 138, 1083, 10.1016/j.cell.2009.06.048 · DOI · Paper page
- Bonizzi, 2012, The emerging role of p53 in stem cells, Trends Mol Med, 18, 6, 10.1016/j.molmed.2011.08.002 · DOI
- Nemunaitis, 2008, Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome, Future Oncol, 4, 759, 10.2217/14796694.4.6.759 · DOI
- Nemunaitis, 2011, Head and neck cancer: response to p53-based therapeutics, Head Neck, 33, 131, 10.1002/hed.21364 · DOI
- Nemunaitis, 2009, Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck, Clin Cancer Res, 15, 7719, 10.1158/1078-0432.CCR-09-1044 · DOI
- Senzer, 2009, A review of contusugene ladenovec (Advexin) p53 therapy, Curr Opin Mol Ther, 11, 54
- Nemunaitis, 2000, Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer, J Clin Oncol, 18, 609, 10.1200/JCO.2000.18.3.609 · DOI · Paper page
- Senzer, 2007, p53 therapy in a patient with Li-Fraumeni syndrome, Mol Cancer Ther, 6, 1478, 10.1158/1535-7163.MCT-07-0125 · DOI
- Swisher, 2003, Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy, Clin Cancer Res, 9, 93
- Daniels, 2012, The transferrin receptor and the targeted delivery of therapeutic agents against cancer, Biochim Biophys Acta, 1820, 291, 10.1016/j.bbagen.2011.07.016 · DOI · Paper page
- Daniels, 2006, The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells, Clin Immunol, 121, 159, 10.1016/j.clim.2006.06.006 · DOI · Paper page
- Daniels, 2006, The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer, Clin Immunol, 121, 144, 10.1016/j.clim.2006.06.010 · DOI · Paper page
- Xu, 2002, Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes, Mol Cancer Ther, 1, 337
- Xu, 1999, Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts, Hum Gene Ther, 10, 2941, 10.1089/10430349950016357 · DOI · Paper page
- Xu, 2002, Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery, Hum Gene Ther, 13, 469, 10.1089/10430340252792594 · DOI
- Xu, 2001, Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv, Mol Med, 7, 723, 10.1007/BF03401962 · DOI
- Yu, 2004, Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide, Nucleic Acids Res, 32, e48, 10.1093/nar/gnh049 · DOI
- Xu, 2001, Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy, J Control Release, 74, 115, 10.1016/S0168-3659(01)00324-8 · DOI
- Yu, 2004, A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene, Gene Ther, 11, 1434, 10.1038/sj.gt.3302304 · DOI
- Chrastina, 2011, Overcoming in vivo barriers to targeted nanodelivery, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 3, 421, 10.1002/wnan.143 · DOI · Paper page
- Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956 · DOI · Paper page
- Pirollo, 2006, Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery, Hum Gene Ther, 17, 117, 10.1089/hum.2006.17.117 · DOI
- Pirollo, 2007, Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system, Cancer Res, 67, 2938, 10.1158/0008-5472.CAN-06-4535 · DOI · Paper page
- Hallaj-Nezhadi, 2010, Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy, Pharmazie, 65, 855
- Guo, 2011, Recent advances in nonviral vectors for gene delivery, Acc Chem Res, 45, 971, 10.1021/ar200151m · DOI · Paper page
- Ahi, 2011, Adenoviral vector immunity: its implications and circumvention strategies, Curr Gene Ther, 11, 307, 10.2174/156652311796150372 · DOI · Paper page
- Monti, 2002, Tumour p53 mutations exhibit promoter selective dominance over wild type p53, Oncogene, 21, 1641, 10.1038/sj.onc.1205250 · DOI
- Harris, 1996, Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein, Cancer Gene Ther, 3, 121
- Wang, 2011, Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation, J Clin Invest, 121, 893, 10.1172/JCI44504 · DOI
- Fujiwara, 1994, Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene, Cancer Res, 54, 2287
Cited by
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Cancer Nanomedicine: From Drug Delivery to Imaging
Chow, E. K.-H., & Ho, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005872 · Cited by 491
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Zhang, R., Qin, X., Kong, F., Chen, P., & Pan, G. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1582730 · Cited by 363
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
Buck, J., Grossen, P., Cullis, P. R., Huwyler, J., & Witzigmann, D. (2019) · ACS Nano · doi:10.1021/acsnano.8b07858 · Cited by 312
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Pearce, A. K., & O’Reilly, R. K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00456 · Cited by 275
Towards principled design of cancer nanomedicine to accelerate clinical translation
Souri, M., Soltani, M., Moradi Kashkooli, F., Kiani Shahvandi, M., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100208 · Cited by 159
Current and Emerging Therapies in Metastatic Pancreatic Cancer
Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145
Non-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Orticello, M., Fiore, M., Totta, P., Desideri, M., Barisic, M., Passeri, D., Lenzi, J., Rosa, A., Orlandi, A., Maiato, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.265 · Cited by 12
Metadata
- Authors
- Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 21
- Issue
- 5
- Pages
- 1096-1103
- ISSN
- 1525-0016
- Cited by
- 236
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1255 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.